Date  |
|
| Dec 20, 2016 |
CEL-SCI Announces Closing of Public Offereing and Receives Audit Opinion with Going Concern Explanation |
| Dec 14, 2016 |
CEL-SCI Reports Fiscal 2016 Financial Results and Clinical & Corporate Developments |
| Dec 9, 2016 |
CEL-SCI Reports on NYSE MKT Noncompliance Notice and Compliance Plan |
| Dec 2, 2016 |
CEL-SCI Announces Pricing of $4.25 Million Public Offering of Common Stock and Warrants |
| Dec 1, 2016 |
CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants |
| Nov 21, 2016 |
CEL-SCI Submits Response to FDA in Connection with Partial Clinical Hold on Phase 3 Clinical Trial |
| Nov 14, 2016 |
CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine is Successful in Treating Rheumatoid Arthritis |
| Oct 21, 2016 |
CEL-SCI Provides Update on Partial Clinical Hold on Phase 3 Clinical Trial |
| Sep 26, 2016 |
CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study |
| Sep 6, 2016 |
CEL-SCI Announces Resignation of its Founder for Health Reasons |